ClinicalTrials.gg
Active, not recruitingNCT05206773PERIDOTUpdated Oct 13, 2026

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

A Phase 3 interventional study of Venglustat (GZ402671) and Placebo in Fabry Disease, sponsored by Sanofi. Active, not recruiting at 50 sites in 21 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Updated Oct 13, 202640 sites added48 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Fabry Disease by Sanofi — 1 open to participants now, 3 under way, 2 of them phase 3. Fabry Disease · Sanofi.

Enrollment
Largest of 19
122 · median 20
Started
2022
with 1 other
Phase 3
4 of 23
none open now
Registered
19th of 23
by date

Among the 23 studies in Fabry Disease by Sanofi, this one has the largest enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 in phase 3, and was the 19th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

1 of the 23 studies in Fabry Disease by Sanofi is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Fabry Disease by Sanofi, or all of them as a file.
02

Study summary

This is a 12-month, parallel treatment, Phase 3, double-blind, randomized, placebo-controlled study to evaluate the effect of venglustat on neuropathic and abdominal pain symptoms of Fabry disease in participants ≥16 years of age with Fabry disease who are treatment-naïve or untreated for at least 6 months.

  • Study visits will take place approximately every 3 months.
  • The double-blind period will be followed by an open-label extension (OLE) during which participants who have completed the double-blind period will be treated with venglustat for an additional 12 months or until the Common Study End of Treatment Day (CSEOTD).
Read the detailed description

Double blind period: the total duration will be up to approximately of 14 months (1 month of screening 12 month of treatment period, and a possible follow-up period of 1 month if no participation in the open label extension period)

Open-label extension period: the total duration will be approximately of 46 months (12 month of OLE treatment, additional OLE treatment until a common study end of treatment date (CSEOTD, approximately 33 months), and 1 month of follow-up period)

03

Conditions studied

  • Fabry Disease

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adult patients 16 year of age or older, who have had a previously confirmed diagnosis of Fabry disease and a history of clinical symptoms of Fabry disease
  • Patients who are treatment-naïve or without prior treatment with an approved or experimental therapy for Fabry disease within at least 6 months prior to screening.
  • Average score of ≥3 (0=no symptom, 10=symptom as bad as you can imagine) on the participant-defined most-bothersome symptom (among neuropathic pain in upper extremities, neuropathic pain in lower extremities, or abdominal pain), as measured by the Fabry Disease Patient-Reported Outcome (FD-PRO) at screening.
  • (with double contraception methods) for male and female participants; not pregnant or breastfeeding for female participants; no sperm donation for male participants.
  • Weight ≥30 Kg
  • A signed must be provided prior to any study-related procedures.

Exclusion criteria

Exclusion Criteria:

  • Any manifestations of Fabry disease that preclude placebo administration.
  • History of , stroke, myocardial infarction, heart failure, evidence of left ventricular hypertrophy and/or cardiac fibrosis, major cardiovascular surgery, or kidney transplantation.
  • History of cardiac arrhythmia. Atrial fibrillation that is well controlled on a stable medical regimen for at least 12 months is not an exclusion if the CHA2DS2-VASc score is 0 for males or 1 for females.
  • Patients with , , or infection.
  • Neuropathic pain in upper or lower extremities, or abdominal pain not related to Fabry disease.
  • History of seizures currently requiring treatment.
  • Uncontrolled hypertension over the past 12 months prior to screening, or systolic BP >=150 or diastolic BP >=100 at screening.
  • Estimated \<60 mL/min/1.73m².
  • Urine protein to creatinine ratio >= 1 g/g at screening.
  • Presence of severe depression as measured by Beck's Depression Inventory (BDI)-II >28 and/or a history of an untreated, unstable major affective disorder within 1 year of the screening visit.
  • Positive SARS-CoV-2 virus test within 2 weeks of enrollment, or COVID 19 requiring hospitalization within 6 months of enrollment.
  • Moderate to severe hepatic impairment.
  • History of drug and/or alcohol abuse.
  • History of or active hepatobiliary disease.
  • Liver enzymes ( (ALT)/aspartate aminotransferase (AST)) or total >2 times the (ULN).
  • Initiation of chronic treatment for pain, or change in pain medication regimen, within 3 months prior to randomization.
  • Strong or moderate inducers or inhibitors of cytochrome P450 3A within 14 days or 5 half-lives, whichever is longer, prior to randomization.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Venglustat

    Participant will receive venglustat dose once daily for 12 months

    Drug: Venglustat (GZ402671)

  • Placebo comparator
    Placebo

    Participants will receive placebo once daily for 12 months

    Drug: Placebo

Interventions

  • Pharmaceutical form: Tablet Route of administration: Oral

  • DrugPlacebo

    Pharmaceutical form: Tablet Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Percent change from baseline at 6 months in the most bothersome symptom of 3 Fabry Disease Patient-Reported Outcome (FD-PRO) items (neuropathic pain in upper extremities, neuropathic pain in lower extremities, or abdominal pain)

    Time frame: From baseline to 6 months

  2. Percent change from baseline at 12 months in the most bothersome symptom of 3 Fabry Disease Patient-Reported Outcome (FD-PRO) items (neuropathic pain in upper extremities, neuropathic pain in lower extremities, or abdominal pain)

    Time frame: From baseline to 12 months

Secondary outcomes

  1. Percent change in plasma globotriaosylsphingosine (lyso-GL-3)

    Time frame: From baseline to 6 month and 12 months

  2. Frequency of rescue pain medication use

    Number of days with use of rescue pain medications during the 6-month treatment period, divided by duration of the 6-month treatment period and multiplied by 100. The same definition will be used for the 12-month period.

    Time frame: From baseline to 6 months and 12 months

  3. Change in the percentage of days with at least 1 stool reflecting diarrhea (Bristol Stool Form Scale [BSFS] Type 6 or 7)

    Time frame: From baseline to 6 month and 12 months

  4. Change in tiredness component of FD-PRO

    Time frame: From baseline to 6 month and 12 months

  5. Proportion of responders in neuropathic or abdominal pain, as assessed by FD-PRO

    Response is defined as at least a 30% decrease from baseline in the most bothersome of 3 FD-PRO items between neuropathic pain in upper extremities, neuropathic pain in lower extremities, and abdominal pain

    Time frame: At 6 months and 12 months

  6. Number of participants with adverse event (AE) and serious adverse event (SAE)

    Time frame: From baseline to 6 month and 12 months

  7. Change in the lens clarity (new or worsening lens opacities) by ophthalmological examination (by slit lamp exam at Visit 2 and Visit 6)

    Time frame: From baseline to 12 months

  8. Change in Beck Depression Inventory-II (BDI-II) score

    Time frame: From baseline to 6 month and 12 months

  9. Plasma venglustat concentrations at prespecified visits over the study duration

    Time frame: From baseline to 6 month and 12 months

  10. Maximum venglustat plasma concentration (Cmax)

    Time frame: From baseline to 6 month and 12 months

  11. Time to maximum venglustat plasma concentration (tmax)

    Time frame: From baseline to 6 month and 12 months

  12. Area under the venglustat plasma concentration versus time curve from time 0 to 24 hours (AUC0-24)

    Time frame: From baseline to 6 month and 12 months

07

Study locations

50 sites
  • University of Alabama -The Kirklin Clinic- Site Number : 8400011
    Birmingham, Alabama 35233, United States
  • David Geffen School of Medicine at UCLA- Site Number : 8400006
    Los Angeles, California 90095, United States
  • University of California Irvine Medical Center- Site Number : 8400019
    Orange, California 92868, United States
  • AdventHealth Orlando- Site Number : 8400008
    Orlando, Florida 32803, United States
  • Emory University School of Medicine - Atlanta- Site Number : 8400010
    Atlanta, Georgia 30322, United States
  • WMCHealth Advanced Physician Services- Site Number : 8400001
    Hawthorne, New York 10532, United States
  • Cincinnati Children's Hospital Medical Center- Site Number : 8400013
    Cincinnati, Ohio 45229-3026, United States
  • UPMC Montefiore- Site Number : 8400009
    Pittsburgh, Pennsylvania 15213, United States
  • Renal Disease Research Institute - Dallas - Live Oak Street- Site Number : 8400012
    Dallas, Texas 75204, United States
  • University of Utah Health Hospital- Site Number : 8400005
    Salt Lake City, Utah 84132, United States
  • Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)- Site Number : 8400004
    Fairfax, Virginia 22030, United States
  • Investigational Site Number : 0320001
    Pergamino, Buenos Aires 2700, Argentina
  • Investigational Site Number : 0320003
    Quilmes, Buenos Aires 1878, Argentina
  • Investigational Site Number : 0320002
    La Rioja, 5300, Argentina
  • Investigational Site Number : 0360001
    Parkville, Victoria 3050, Australia
  • Investigational Site Number : 0400001
    Vienna, 1090, Austria
  • Hospital de Clinicas de Porto Alegre- Site Number : 0760001
    Porto Alegre, Rio Grande do Sul 90035903, Brazil
  • Instituto de Genética e Erros Inatos do Metabolismo- Site Number : 0760002
    São Paulo, 04020-041, Brazil
  • Investigational Site Number : 1240003
    Calgary, Alberta T2E 7Z4, Canada
  • Investigational Site Number : 1240001
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Investigational Site Number : 1240005
    Toronto, Ontario M5T 3H7, Canada
  • Investigational Site Number : 1560001
    Beijing, 100034, China
  • Investigational Site Number : 1560003
    Shanghai, 200025, China
  • Investigational Site Number : 1560004
    Taiyuan, 030001, China
  • Investigational Site Number : 1560006
    Zhengzhou, 450052, China
  • Investigational Site Number : 2080001
    Copenhagen, 2100, Denmark
  • Investigational Site Number : 2460001
    Turku, 20521, Finland
  • Investigational Site Number : 2500001
    Garches, 92380, France
  • Investigational Site Number : 2760003
    Munich, 80337, Germany
  • Investigational Site Number : 2760001
    Würzburg, 97080, Germany
  • Investigational Site Number : 3000003
    Athens, 115 28, Greece
  • Investigational Site Number : 3000002
    Ioannina, 455 00, Greece
  • Investigational Site Number : 3800001
    Naples, Napoli 80131, Italy
  • Investigational Site Number : 3800004
    Rome, Roma 00168, Italy
  • Investigational Site Number : 3800005
    Bologna, 40138, Italy
  • Investigational Site Number : 3920004
    Fukuoka, 814-0180, Japan
  • Investigational Site Number : 3920003
    Tokyo, 105-8461, Japan
  • Investigational Site Number : 4840001
    Monterrey, Nuevo León 64460, Mexico
  • Investigational Site Number : 4840002
    Mexico City, 06700, Mexico
  • Investigational Site Number : 5780001
    Bergen, 5021, Norway
  • Investigational Site Number : 6160002
    Poznan, Greater Poland Voivodeship 60-780, Poland
  • Investigational Site Number : 6160003
    Wroclaw, Lower Silesian Voivodeship 50-556, Poland
  • Investigational Site Number : 6160004
    Rzeszów, Podkarpackie Voivodeship 35-301, Poland
  • Investigational Site Number : 6420001
    Bucharest, 022328, Romania
  • Investigational Site Number : 7560001
    Zurich, 8091, Switzerland
  • Investigational Site Number : 7920001
    Ankara, 06560, Turkey (Türkiye)
  • Investigational Site Number : 7920002
    İzmit, 41001, Turkey (Türkiye)
  • Investigational Site Number : 8260001
    Cambridge, Cambridgeshire CB2 2QQ, United Kingdom
  • Investigational Site Number : 8260002
    London, England NW3 2QG, United Kingdom
  • Investigational Site Number : 8260003
    Salford, Manchester M6 8HD, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Dec 2025, 45 months.

Of 22 phase 3 interventional studies under Fabry Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's 45 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2021
First posted
Jan 25, 2022
StartActual
Mar 11, 2022
Primary completionActual
Dec 17, 2025
CompletionEst.
Jan 4, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
40 sites added, 48 sites removed
Show 40 added (10 United States, 3 Argentina, 3 Canada, 3 China, 3 Italy, 2 Brazil, 2 Germany, 2 Japan, 2 Mexico, 2 Poland, 2 United Kingdom, 1 Austria, 1 Denmark, 1 Finland, 1 Greece, 1 Norway, 1 Romania)
  • University of Alabama -The Kirklin Clinic- Site Number : 8400011 · Birmingham, United States
  • David Geffen School of Medicine at UCLA- Site Number : 8400006 · Los Angeles, United States
  • AdventHealth Orlando- Site Number : 8400008 · Orlando, United States
  • Emory University School of Medicine - Atlanta- Site Number : 8400010 · Atlanta, United States
  • WMCHealth Advanced Physician Services- Site Number : 8400001 · Hawthorne, United States
  • Cincinnati Children's Hospital Medical Center- Site Number : 8400013 · Cincinnati, United States
  • UPMC Montefiore- Site Number : 8400009 · Pittsburgh, United States
  • Renal Disease Research Institute - Dallas - Live Oak Street- Site Number : 8400012 · Dallas, United States
  • University of Utah Health Hospital- Site Number : 8400005 · Salt Lake City, United States
  • Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)- Site Number : 8400004 · Fairfax, United States
  • Investigational Site Number : 0320001 · Pergamino, Argentina
  • Investigational Site Number : 0320003 · Quilmes, Argentina
  • Investigational Site Number : 0320002 · La Rioja, Argentina
  • Investigational Site Number : 0400001 · Vienna, Austria
  • Hospital de Clinicas de Porto Alegre- Site Number : 0760001 · Porto Alegre, Brazil
  • Instituto de Genética e Erros Inatos do Metabolismo- Site Number : 0760002 · São Paulo, Brazil
  • Investigational Site Number : 1240003 · Calgary, Canada
  • Investigational Site Number : 1240001 · Halifax, Canada
  • Investigational Site Number : 1240005 · Toronto, Canada
  • Investigational Site Number : 1560001 · Beijing, China
  • Investigational Site Number : 1560003 · Shanghai, China
  • Investigational Site Number : 1560004 · Taiyuan, China
  • Investigational Site Number : 2080001 · Copenhagen, Denmark
  • Investigational Site Number : 2460001 · Turku, Finland
  • Investigational Site Number : 2760003 · Munich, Germany
  • Investigational Site Number : 2760001 · Würzburg, Germany
  • Investigational Site Number : 3000002 · Ioannina, Greece
  • Investigational Site Number : 3800001 · Naples, Italy
  • Investigational Site Number : 3800004 · Rome, Italy
  • Investigational Site Number : 3800005 · Bologna, Italy
  • …and 10 more on the registry record
Show 48 removed
  • Nephrology Clinic at Kirklin Clinic of UAB Hospital_Investigational Site Number: 8400011 · Birmingham, United States
  • UCLA Medical Center_Investigational Site Number: 8400006 · Los Angeles, United States
  • Advent Health Orlando_Investigational Site Number: 8400008 · Orlando, United States
  • Emory Genetics- Site Number : 8400010 · Atlanta, United States
  • Westchester Medical Center Healthcare Corporation- Site Number : 8400001 · Hawthorne, United States
  • Cincinnati Children's Hospital Medical Center - PIN- Site Number : 8400013 · Cincinnati, United States
  • Cleveland Clinic Site Number : 8400016 · Cleveland, United States
  • Children's Hospital Of Pittsburgh- Site Number : 8400009 · Pittsburgh, United States
  • Renal Disease Research Institute, An affiliate of: Dallas Nephrology Associates_Investigational Site Number: 8400012 · Dallas, United States
  • University Of Utah Health Sciences Center- Site Number : 8400005 · Salt Lake City, United States
  • Lysosomal and Rare Disorders Research and Treatment Center_Investigational Site Number: 8400004 · Fairfax, United States
  • Fundacion Cori para la Investigación y Prevención del Cancer_Investigational Site Number: 0320002 · La Rioja, Argentina
  • Instituto de Investigaciones Clínicas Quilmes (IICQ) SRL_Investigational Site Number: 0320003 · Quilmes, Argentina
  • Investigational Site Number: 0400001 · Vienna, Austria
  • Hospital de Clínicas de Porto Alegre_Investigational Site Number: 0760001 · Porto Alegre, Brazil
  • Instituto de Genética e Erros Inatos do Metabolismo - IGEIM- Site Number : 0760002 · São Paulo, Brazil
  • M.A.G.I.C Calgary LTD_Investigational Site Number: 1240003 · Calgary, Canada
  • Medicine Dalhousie University_Investigational Site Number : 1240001 · Halifax, Canada
  • University Health Network_Investigational Site Number : 1240005 · Toronto, Canada
  • No.8, Xishiku Street, Xicheng District_Site Number: 1560001 · Beijing, China
  • No.197,2nd Ruijin road, Huangpu district_Site Number: 1560003 · Shanghai, China
  • No.85 South Jiefang road, Yingze District_Site Number: 1560004 · Taiyuan, China
  • Investigational Site Number: 2080001 · Copenhagen, Denmark
  • Investigational Site Number: 2460001 · Turku, Finland
  • ISphinCS GmbH_Investigational Site Number: 2760004 · Hochheim am Main, Germany
  • Investigational Site Number : 2760005 · Mainz, Germany
  • Investigational Site Number: 2760003 · München, Germany
  • Investigational Site Number: 2760001 · Würzburg, Germany
  • University Hospital of Heraklion_Investigational Site Number: 3000001 · Heraklion, Greece
  • University Hospital of Ioannina_Investigational Site Number: 3000002 · Ioannina, Greece
  • …and 18 more on the registry record
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    40 sites added, 48 sites removed
    Show 40 added (10 United States, 3 Argentina, 3 Canada, 3 China, 3 Italy, 2 Brazil, 2 Germany, 2 Japan, 2 Mexico, 2 Poland, 2 United Kingdom, 1 Austria, 1 Denmark, 1 Finland, 1 Greece, 1 Norway, 1 Romania)
    • University of Alabama -The Kirklin Clinic- Site Number : 8400011 · Birmingham, United States
    • David Geffen School of Medicine at UCLA- Site Number : 8400006 · Los Angeles, United States
    • AdventHealth Orlando- Site Number : 8400008 · Orlando, United States
    • Emory University School of Medicine - Atlanta- Site Number : 8400010 · Atlanta, United States
    • WMCHealth Advanced Physician Services- Site Number : 8400001 · Hawthorne, United States
    • Cincinnati Children's Hospital Medical Center- Site Number : 8400013 · Cincinnati, United States
    • UPMC Montefiore- Site Number : 8400009 · Pittsburgh, United States
    • Renal Disease Research Institute - Dallas - Live Oak Street- Site Number : 8400012 · Dallas, United States
    • University of Utah Health Hospital- Site Number : 8400005 · Salt Lake City, United States
    • Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)- Site Number : 8400004 · Fairfax, United States
    • Investigational Site Number : 0320001 · Pergamino, Argentina
    • Investigational Site Number : 0320003 · Quilmes, Argentina
    • Investigational Site Number : 0320002 · La Rioja, Argentina
    • Investigational Site Number : 0400001 · Vienna, Austria
    • Hospital de Clinicas de Porto Alegre- Site Number : 0760001 · Porto Alegre, Brazil
    • Instituto de Genética e Erros Inatos do Metabolismo- Site Number : 0760002 · São Paulo, Brazil
    • Investigational Site Number : 1240003 · Calgary, Canada
    • Investigational Site Number : 1240001 · Halifax, Canada
    • Investigational Site Number : 1240005 · Toronto, Canada
    • Investigational Site Number : 1560001 · Beijing, China
    • Investigational Site Number : 1560003 · Shanghai, China
    • Investigational Site Number : 1560004 · Taiyuan, China
    • Investigational Site Number : 2080001 · Copenhagen, Denmark
    • Investigational Site Number : 2460001 · Turku, Finland
    • Investigational Site Number : 2760003 · Munich, Germany
    • Investigational Site Number : 2760001 · Würzburg, Germany
    • Investigational Site Number : 3000002 · Ioannina, Greece
    • Investigational Site Number : 3800001 · Naples, Italy
    • Investigational Site Number : 3800004 · Rome, Italy
    • Investigational Site Number : 3800005 · Bologna, Italy
    • …and 10 more on the registry record
    Show 48 removed
    • Nephrology Clinic at Kirklin Clinic of UAB Hospital_Investigational Site Number: 8400011 · Birmingham, United States
    • UCLA Medical Center_Investigational Site Number: 8400006 · Los Angeles, United States
    • Advent Health Orlando_Investigational Site Number: 8400008 · Orlando, United States
    • Emory Genetics- Site Number : 8400010 · Atlanta, United States
    • Westchester Medical Center Healthcare Corporation- Site Number : 8400001 · Hawthorne, United States
    • Cincinnati Children's Hospital Medical Center - PIN- Site Number : 8400013 · Cincinnati, United States
    • Cleveland Clinic Site Number : 8400016 · Cleveland, United States
    • Children's Hospital Of Pittsburgh- Site Number : 8400009 · Pittsburgh, United States
    • Renal Disease Research Institute, An affiliate of: Dallas Nephrology Associates_Investigational Site Number: 8400012 · Dallas, United States
    • University Of Utah Health Sciences Center- Site Number : 8400005 · Salt Lake City, United States
    • Lysosomal and Rare Disorders Research and Treatment Center_Investigational Site Number: 8400004 · Fairfax, United States
    • Fundacion Cori para la Investigación y Prevención del Cancer_Investigational Site Number: 0320002 · La Rioja, Argentina
    • Instituto de Investigaciones Clínicas Quilmes (IICQ) SRL_Investigational Site Number: 0320003 · Quilmes, Argentina
    • Investigational Site Number: 0400001 · Vienna, Austria
    • Hospital de Clínicas de Porto Alegre_Investigational Site Number: 0760001 · Porto Alegre, Brazil
    • Instituto de Genética e Erros Inatos do Metabolismo - IGEIM- Site Number : 0760002 · São Paulo, Brazil
    • M.A.G.I.C Calgary LTD_Investigational Site Number: 1240003 · Calgary, Canada
    • Medicine Dalhousie University_Investigational Site Number : 1240001 · Halifax, Canada
    • University Health Network_Investigational Site Number : 1240005 · Toronto, Canada
    • No.8, Xishiku Street, Xicheng District_Site Number: 1560001 · Beijing, China
    • No.197,2nd Ruijin road, Huangpu district_Site Number: 1560003 · Shanghai, China
    • No.85 South Jiefang road, Yingze District_Site Number: 1560004 · Taiyuan, China
    • Investigational Site Number: 2080001 · Copenhagen, Denmark
    • Investigational Site Number: 2460001 · Turku, Finland
    • ISphinCS GmbH_Investigational Site Number: 2760004 · Hochheim am Main, Germany
    • Investigational Site Number : 2760005 · Mainz, Germany
    • Investigational Site Number: 2760003 · München, Germany
    • Investigational Site Number: 2760001 · Würzburg, Germany
    • University Hospital of Heraklion_Investigational Site Number: 3000001 · Heraklion, Greece
    • University Hospital of Ioannina_Investigational Site Number: 3000002 · Ioannina, Greece
    • …and 18 more on the registry record
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05206773
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 25, 2022
Start date
Mar 11, 2022
Primary completion
Dec 17, 2025
Completion
Jan 4, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venglustat

Start the discussion